In the SELECT trial (among others), it showed lower rates of major adverse cardiovascular events (such as heart attacks and strokes) compared to placebo, especially in overweight or obese patients
Does IIH cause brain fog or cognitive problems
A time-limited trial (e.g., 4 weeks) may help determine if they're beneficial for you
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH
Key areas to watch include: Improved drug formulations with extended-release options Combination therapies involving GLP-1 agonists Personalized treatment plans enhanced by genetic profiling Expansion of GLP-1 applications to other metabolic health conditions Advancements in these areas may lead to better treatment adherence and effectiveness